NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Epidemiology and Biomarker Study in Alzheimer's Disease

RecruitingPhase 3

Sponsor: Eli Lilly and Company

Conditions: Alzheimer Disease

Interventions: P-tau217 Test

Countries: United States, Japan

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Eligibility overview

Sex: ALL

Age: 55 Years to 75 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* The participant must self-report unimpaired cognition.
* The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

Exclusion Criteria:

* Have seen a doctor about memory concerns.
* Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
* Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
* Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.

Locations (4)

Houston, Texas, United States
Bunkyō City, Japan
Tokyo, Japan
Tokyo, Japan